Literature DB >> 8214276

Predictors of treatment failure in multiple drug-resistant falciparum malaria: results from a 42-day follow-up of 224 patients in eastern Thailand.

A L Fontanet1, A M Walker.   

Abstract

We report here the results of a 42-day follow-up of 224 patients treated with mefloquine for uncomplicated falciparum malaria in Eastern Thailand. The risk of treatment failure among the 209 patients who completed the follow-up was 57% (95% confidence interval [CI] = 50,64). The daily risk of treatment failure, estimated through an exponential survival function, was constant during the follow-up period and equal to 1.9%. Five patient characteristics were found to be independent and important predictors of treatment failure in a Cox proportional hazards model: a young age (adjusted hazard ratio [AHR] for an increase of 10 years of age = 0.75 [95% CI = 0.62, 0.90]); a history of at least three documented mefloquine treatments in the past year (AHR = 1.89 [95% CI = 1.10, 3.24]); a parasitemia count > 100,000/microliter (AHR = 1.80 [95% CI = 1.16, 2.80]); and a history of diarrhea in the first two days after treatment (AHR = 1.51 [95% CI = 0.99, 2.31]). A hemoglobin level < or = 10 g/dl on the day of consultation was also a predictor of treatment failure, but only among patients who had been treated for malaria in the past 120 days (AHR = 4.38 [95% CI = 1.55, 12.1]). These latter patients may have become anemic while they were unsuccessfully treated with mefloquine for an infection by a multiple drug-resistant strain in the past 120 days.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8214276     DOI: 10.4269/ajtmh.1993.49.465

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

1.  An old enemy, a new battle plan. Perspective on combating drug-resistant malaria.

Authors:  A F Cowman; M T Duraisingh
Journal:  EMBO Rep       Date:  2001-02       Impact factor: 8.807

Review 2.  Assessment of the pharmacodynamic properties of antimalarial drugs in vivo.

Authors:  N J White
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

3.  Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients.

Authors:  F O ter Kuile; F Nosten; C Luxemburger; D Kyle; P Teja-Isavatharm; L Phaipun; R Price; T Chongsuphajaisiddhi; N J White
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

4.  Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children.

Authors:  Akintunde Sowunmi; Elsie O Adewoye; Grace O Gbotsho; Christian T Happi; Abayomi Sijuade; Onikepe A Folarin; Titilope M Okuboyejo; Obaro S Michael
Journal:  Malar J       Date:  2010-02-15       Impact factor: 2.979

5.  Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics.

Authors:  Nicholas M Douglas; François Nosten; Elizabeth A Ashley; Lucy Phaiphun; Michèle van Vugt; Pratap Singhasivanon; Nicholas J White; Ric N Price
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

6.  Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial.

Authors:  Elizabeth N Allen; Francesca Little; Tunisio Camba; Yasmin Cassam; Jaishree Raman; Andrew Boulle; Karen I Barnes
Journal:  Malar J       Date:  2009-06-26       Impact factor: 2.979

7.  Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies.

Authors:  Wirichada Pongtavornpinyo; Shunmay Yeung; Ian M Hastings; Arjen M Dondorp; Nicholas P J Day; Nicholas J White
Journal:  Malar J       Date:  2008-11-02       Impact factor: 2.979

8.  Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax.

Authors:  Nicholas M Douglas; Julie A Simpson; Aung Pyae Phyo; Hadjar Siswantoro; Armedy R Hasugian; Enny Kenangalem; Jeanne Rini Poespoprodjo; Pratap Singhasivanon; Nicholas M Anstey; Nicholas J White; Emiliana Tjitra; Francois Nosten; Ric N Price
Journal:  J Infect Dis       Date:  2013-06-12       Impact factor: 5.226

9.  The prevalence and degree of resistance of Plasmodium falciparum to first-line antimalarial drugs: an in vitro study from a malaria endemic region in Yemen.

Authors:  Hassan Al-Shamahy; Abdullilah Hussein Al-Harazy; Nabil S Harmal; Abdulgodos M Al-Kabsi
Journal:  Ann Saudi Med       Date:  2007 Nov-Dec       Impact factor: 1.526

10.  Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malaria.

Authors:  Michael Nambozi; Jean-Bertin Bukasa Kabuya; Sebastian Hachizovu; David Mwakazanga; Joyce Mulenga; Webster Kasongo; Jozefien Buyze; Modest Mulenga; Jean-Pierre Van Geertruyden; Umberto D'Alessandro
Journal:  Malar J       Date:  2017-05-16       Impact factor: 2.979

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.